Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.
Immune thrombocytopenia (ITP) is an acquired bleeding autoimmune disorder characterized by a markedly decreased blood platelet count. The disorder is variable, frequently having an acute onset of limited duration in children and a more chronic course in adults. A number of therapeutic agents have demonstrated efficacy in increasing the platelet counts in both children and adults. Anti-RhD immunoglobulin (anti-D) is one such agent, and has been successfully used in the setting of both acute and chronic immune thrombocytopenia. In this report we review the use of anti-D in the management of ITP. While the FDA-approved dose of 50 mg/kg has documented efficacy in increasing platelet counts in approximately 80% of children and 70% of adults, a higher dose of 75 microg/kg has been shown to result in a more rapid increase in platelet count without a greater reduction in hemoglobin. Anti-D is generally ineffective in patients who have failed splenectomy. Anti-RhD therapy has been shown capable of delaying splenectomy in adult patients, but does not significantly increase the total number of patients in whom the procedure can be avoided. Anti-D therapy appears to inhibit macrophage phagocytosis by a combination of both FcR blockade and inflammatory cytokine inhibition of platelet phagocytosis within the spleen. Anti-RhD treatment is associated with mild to moderate infusion toxicities. Rare life-threatening toxicities such as hemoglobinuria, acute renal failure and disseminated intravascular coagulation have been reported. Recommendations have been proposed to reduce the risk of these complications. Anti-D immunoglobulin can be an effective option for rapidly increasing platelet counts in patients with symptomatic ITP.
Cheung
Eric
E
Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California-Keck School of Medicine, Los Angeles, CA, USA.
Liebman
Howard A
HA
Blood. 1991 May 1;77(9):1884-93
1850307
Blood. 2002 Mar 15;99(6):1922-7
11877261
Haematologica. 1987 Nov-Dec;72(6):529-32
3126110
Blut. 1986 Feb;52(2):117-21
3081067
Zentralbl Gynakol. 1997;119(5):204-10
9281253
Blood. 2004 Feb 15;103(4):1364-9
14576051
Blood. 1988 May;71(5):1499-502
2833961
Br J Haematol. 1994 Nov;88(3):618-20
7819076
Am J Hematol. 2003 Nov;74(3):161-9
14587042
Blut. 1984 Jul;49(1):29-35
6430368
Am J Hematol. 1986 Jul;22(3):241-50
3087158
Curr Opin Hematol. 2007 Sep;14(5):526-34
17934363
Blood. 2005 Sep 1;106(5):1532-7
15878975
Clin Lab Haematol. 1988;10(3):275-84
2846228
Lancet. 1994 Sep 10;344(8924):703-7
7915773
Semin Hematol. 1998 Jan;35(1 Suppl 1):9-13
9523744
Blood. 2007 Jun 15;109(12):5527; author reply 5528
17554071
Nat Med. 2006 Jun;12(6):688-92
16715090
Blood. 1997 Apr 15;89(8):2689-700
9108386
Br J Haematol. 2004 Feb;124(4):511-8
14984503
Blood. 2003 Oct 15;102(8):2862-7
12829590
Br J Haematol. 1992 Mar;80(3):337-40
1581213
Can Med Assoc J. 1980 Dec 6;123(11):1121-7
6161687
J Pediatr. 1992 Apr;120(4 Pt 1):522-7
1313096
Eur J Pediatr. 1986 Aug;145(3):166-9
3021462
Semin Hematol. 2007 Oct;44(4 Suppl 5):S24-34
18096469
Lancet. 2008 Feb 2;371(9610):395-403
18242413
Br J Haematol. 2001 Mar;112(4):1076-8
11298610
Curr Opin Hematol. 2007 Sep;14(5):511-4
17934360
Transfus Med Rev. 2008 Apr;22(2):103-16
18353251
Vox Sang. 2007 Aug;93(2):99-111
17683353
Blood. 2000 Apr 15;95(8):2523-9
10753830
Br J Haematol. 2008 Apr;141(1):109-19
18279459
N Engl J Med. 2002 Mar 28;346(13):995-1008
11919310
Curr Opin Hematol. 2007 Sep;14(5):535-56
17934364
Haematologica. 1992 May-Jun;77(3):248-52
1330848